Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Scope Extension to include Manufacturing

23rd Nov 2011 07:00

RNS Number : 5845S
Sphere Medical Holding plc
23 November 2011
 



 

23 November 2011

Sphere Medical Holding plc

EN ISO13485 Scope Extension to include Manufacturing

 

 

Cambridge, UK, 23 November 2011: Sphere Medical Holding plc (AIM:SPHR.L) ("Sphere Medical" or the "Company"), a leading developer of innovative patient monitoring and diagnostic products for the critical care market, is pleased to announce that it has received formal certification by its Notified Body, TÜV SÜD Product Service GmbH, of the extension of its existing EN ISO13485 for Design and Development to include production of Medical Monitoring Systems.

This extension now enables Sphere Medical to manufacture its monitoring and diagnostic medical devices, including its Proxima disposable patient-attached arterial blood analyser, at its manufacturing facility in Harston, Cambridge.

Commenting on the EN ISO13485 scope extension, Chief Executive Officer, Dr Stuart Hendry, said:

"The successful completion of the audit and certification by TÜV SÜD, our notified body, validates the excellent quality management system which we have at Sphere Medical. This scope extension is an important achievement and underpins our capability for commercial manufacture at our Harston facility."

 

For further information, please contact:

 

Sphere Medical Holding plc Tel: +44 (0)1223 875222

Dr Stuart Hendry, Chief Executive Officer

Matthew Hall, Chief Financial Officer

 

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Dr Vijay Barathan

 

Buchanan Communications Tel: +44 (0) 20 7466 5000

Tim Anderson

Lisa Baderoon

 

www.spheremedical.com 

 

Notes for Editors

Sphere Medical is a UK based medical device company completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere Medical's products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient's bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.

Sphere Medical's two most advanced products, based on its proprietary microanalyser platform technology, are a disposable patient-attached arterial blood analyser for use in the Intensive Care Unit and Operating Room ('Proxima') and a device for continuous blood monitoring in the bypass circuit in patients undergoing cardiopulmonary bypass surgery ("CPB device"). Sphere Medical has also developed and is selling a device ('Pelorus 1000') that can measure blood levels of the intravenously administered anaesthetic drug, propofol. In each case, these products will ultimately target patients requiring close monitoring and frequent levels of blood testing.

Sphere Medical employs 43 staff in the areas of research and development, product development, sales and marketing and management and operations at its premises at Harston, Cambridge, UK.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFAAFFFFFF

Related Shares:

Sphere Medical Holding
FTSE 100 Latest
Value8,415.25
Change0.00